{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:50:35Z","timestamp":1790923835777,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,16]],"date-time":"2018-06-16T00:00:00Z","timestamp":1529107200000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic Cancer Center"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-14-OCRP-IIRA OC140298"],"award-info":[{"award-number":["W81XWH-14-OCRP-IIRA OC140298"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CTSA","award":["UL1 TR000135"],"award-info":[{"award-number":["UL1 TR000135"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ygyno.2017.04.022","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T19:15:18Z","timestamp":1495480518000},"page":"187-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Quinacrine in endometrial cancer: Repurposing an old antimalarial drug"],"prefix":"10.1016","volume":"146","author":[{"given":"Eleftheria","family":"Kalogera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debarshi","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean C.","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viji","family":"Shridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.04.022_bb0005","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0010","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0015","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0020","first-page":"47","article-title":"The United States Army and malaria control in World War II","volume":"42","author":"Hays","year":"2000","journal-title":"Parassitologia"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0025","first-page":"573","article-title":"Studies on the administration of quinacrine to tumor-bearing mice","volume":"15","author":"Vassey","year":"1955","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/1097-0142(197304)31:4<899::AID-CNCR2820310421>3.0.CO;2-2","article-title":"Single-dose quinacrine (atabrine) and thoracostomy in the control of pleural effusions in patients with neoplastic diseases","volume":"31","author":"Borja","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0035","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/onc.2008.460","article-title":"9-Aminoacridine-based anticancer drugs target the PI3K\/AKT\/mTOR, NF-kappaB and p53 pathways","volume":"28","author":"Guo","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4161\/cbt.4.8.2134","article-title":"Acridine derivatives activate p53 and induce tumor cell death through Bax","volume":"4","author":"Wang","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0045","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1073\/pnas.0508888102","article-title":"Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors","volume":"102","author":"Gurova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0050","doi-asserted-by":"crossref","first-page":"19162","DOI":"10.1074\/jbc.M109.091645","article-title":"Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin","volume":"285","author":"Jani","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0055","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ijc.26158","article-title":"Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity","volume":"130","author":"Preet","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0060","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1471-2407-10-370","article-title":"Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells","volume":"10","author":"Sasaki","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4161\/cbt.12.3.17033","article-title":"Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents","volume":"12","author":"Wang","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejphar.2008.11.044","article-title":"Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II","volume":"602","author":"Oppegard","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0075","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1158\/1078-0432.CCR-07-1591","article-title":"Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer","volume":"13","author":"Friedman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0080","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/bjc.1997.272","article-title":"Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine","volume":"75","author":"de Souza","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0085","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1158\/0008-5472.CAN-05-3582","article-title":"HSulf-1 inhibits angiogenesis and tumorigenesis in vivo","volume":"66","author":"Narita","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0090","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1593\/neo.11148","article-title":"Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo","volume":"13","author":"Rattan","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/cbt.12.3.17034","article-title":"Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer","volume":"12","author":"Gallant","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0100","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10495-007-0165-6","article-title":"Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol","volume":"13","author":"Gagnon","year":"2008","journal-title":"Apoptosis"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0110","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.18632\/oncotarget.2157","article-title":"MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells","volume":"5","author":"Konno","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2017.04.022_bb0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.1995.13.3.765","article-title":"Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool","volume":"13","author":"Gasparini","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.022_bb0125","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730803X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730803X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:37:25Z","timestamp":1758771445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581730803X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S009082581730803X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinacrine in endometrial cancer: Repurposing an old antimalarial drug","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}